博瑞医药(688166.SH)：BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果

智通财经03-24

智通财经APP讯，博瑞医药(688166.SH)发布公告，近日，博瑞生物医药(苏州)股份有限公司及全资子公司博瑞制药(苏州)有限公司(以下合称“公司”)自主研发的BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得了积极结果。BGM0504片是公司自主研发的GLP-1(胰高血糖素样肽1)和GIP(葡萄糖依赖性促胰岛素多肽)受体双重激动剂，属于境内外均未上市化学药品1类创新药。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2621174052?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-24 16:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621174052","market":"us","top_or_hot":-1,"title":"博瑞医药(688166.SH)：BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果","media":"智通财经","content":"<div>\n<p>智通财经APP讯，博瑞医药(688166.SH)发布公告，近日，博瑞生物医药(苏州)股份有限公司及全资子公司博瑞制药(苏州)有限公司(以下合称“公司”)自主研发的BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得了积极结果。BGM0504片是公司自主研发的GLP-1(胰高血糖素样肽1)和GIP(葡萄糖依赖性促胰岛素多肽)受体双重激动剂，属于境内外均未上市化学药品1类创新药。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417994.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博瑞医药(688166.SH)：BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博瑞医药(688166.SH)：BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 16:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1417994.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，博瑞医药(688166.SH)发布公告，近日，博瑞生物医药(苏州)股份有限公司及全资子公司博瑞制药(苏州)有限公司(以下合称“公司”)自主研发的BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得了积极结果。BGM0504片是公司自主研发的GLP-1(胰高血糖素样肽1)和GIP(葡萄糖依赖性促胰岛素多肽)受体双重激动剂，属于境内外均未上市化学药品1类创新药。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1417994.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688166","symbol_name":"博瑞医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1417994.html","article_id":"2621174052","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621174052","pubTimestamp":1774340604,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，博瑞医药(688166.SH)发布公告，近日，博瑞生物医药(苏州)股份有限公司及全资子公司博瑞制药(苏州)有限公司(以下合称“公司”)自主研发的BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得了积极结果。BGM0504片是公司自主研发的GLP-1(胰高血糖素样肽1)和GIP(葡萄糖依赖性促胰岛素多肽)受体双重激动剂，属于境内外均未上市化学药品1类创新药。2025年8月和9月，公司分别收到美国食品药品监督管理局和中国国家药品监督管理局签发的《药物临床试验批准通知书》，同意BGM0504片在中国和美国参与者上开展关于成人超重/肥胖适应症的临床试验。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688166":"博瑞医药","BK0239":"医药制造"},"translate_title":"Borui Pharma (688166.SH): Positive results in Phase I clinical trial of BGM0504 tablets in Chinese and US participants for the treatment of adult overweight/obesity","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688166":1.5},"content_text":"智通财经APP讯，博瑞医药(688166.SH)发布公告，近日，博瑞生物医药(苏州)股份有限公司及全资子公司博瑞制药(苏州)有限公司(以下合称“公司”)自主研发的BGM0504片在中国和美国参与者上治疗成人超重/肥胖的I期临床试验取得了积极结果。BGM0504片是公司自主研发的GLP-1(胰高血糖素样肽1)和GIP(葡萄糖依赖性促胰岛素多肽)受体双重激动剂，属于境内外均未上市化学药品1类创新药。2025年8月和9月，公司分别收到美国食品药品监督管理局和中国国家药品监督管理局签发的《药物临床试验批准通知书》，同意BGM0504片在中国和美国参与者上开展关于成人超重/肥胖适应症的临床试验。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621174052","isCrawlerRequest":true}